Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Urinary Bladder Neoplasms 9Carcinoma, Transitional Cell 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Ureteral Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Urogenital Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Kidney Neoplasms 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × vinflunine × Clear all
NCT01095003 2022-04-28

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Pierre Fabre Medicament

Phase 3 Completed
770 enrolled 13 charts
Breast

Breast Neoplasms

NCT01091168 2019-09-16

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Pierre Fabre Medicament

Phase 3 Completed
594 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01953003 2019-05-02

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Pierre Fabre Medicament

Phase 3 Completed
112 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡